Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Multiferon for locoregional metastases in malignant melanoma (AJCC IIIB/C)
2010-022103-21Phase 2Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Nov 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon alfa in cutaneous melanoma (CM) and melanoma, sponsored by University Hospital Tübingen. Primary endpoint: Overall response rate at 4 weeks. Started Nov 2010; status: terminated.
02
Drugs
interferon alfa
03
Conditions
cutaneous melanoma (CM)melanoma
Beyond the preview
Go deeper on 2010-022103-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022103-21.